Clinical trials: Botulinum toxin type A
Glabellar Frown Lines
Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Glabellar Lines
An interventional phase 3 study to evaluate efficacy and safety of a new dilution and injection volume of AbobotulinumtoxinA treatment for glabellar lines
- Trial name
- NCT03960957
- Testing
- AbobotulinumtoxinA
- Where
- 11 sites in United States
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Lateral Canthal Lines
Treatment of Moderate to Severe Lateral Canthal Lines
The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe LCL.
- Trial name
- READY-2 (NCT04249687)
- Testing
- botulinum toxin
- Where
- 10 sites in United States, Canada
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Overactive Bladder
Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.
- Trial name
- NCT00910520
- Testing
- onabotulinumtoxinA, normal saline
- Where
- 7 sites in United States, Belgium and 5 more
- Volunteers
- 548 people
- Sponsor
- Allergan
Sun-induced Wrinkles
Safety and Efficacy of the Full Face Applications of Variable Doses of a Commercial Botulinum Toxin Type a (Dysport®)
This is an open-label and phase IV study of full face injections of variable doses of botulinum toxin type A (BT-A). As it is an open-label and not blind study, both investigator and subjects will know the injection local and…
- Trial name
- NCT01032954
- Testing
- Botulinum toxin
- Where
- Brazil
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Hexsel Dermatology Clinic
Spinal Cord Injuries
Effect of Botulinum Toxin A on Detrusor Overactivity and Renal Function in Chronic Spinal Cord Injured Patients
To investigate the clinical effect of detrusor botulinum toxin A (BoNT-A) injection on neurogenic detrusor overactivity (NDO) and renal function and to compare the difference of expressions of sensory receptors and nerve growth…
- Trial name
- NCT01682603
- Testing
- Botulinum toxin A
- Where
- Taiwan
- Volunteers
- 34 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Cervical Dystonia
Study Comparing Short Term Efficacy of Dysport and Dysport NG to Placebo, and to Assess Efficacy and Safety of Dysport NG of Subjects With Cervical Dystonia
The purpose of this study is to evaluate how well a new drug called Dysport NG works and how safe it is, when it is used for the treatment of cervical dystonia. Dysport NG will be compared to an approved drug called Dysport.
- Trial name
- NCT01261611
- Testing
- Botulinum toxin type A
- Where
- 57 sites in Australia, Austria and 9 more
- Volunteers
- 382 people
- Sponsor
- Ipsen
Essential Tremor of the Upper Limbs
Botulinum Toxin A to Treat Arm Tremor
The objective of this study is to assess the efficacy and safety of a single, kinematic-analysis-based intramuscular injection of NT 201, compared with placebo, in moderate to marked essential tremor of the upper limb.
- Trial name
- NCT02207946
- Testing
- IncobotulinumtoxinA
- Where
- 6 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Merz Pharmaceuticals GmbH
Tremor
Kinematic-guided BoNT-A Treatment for ET and PD Tremor
The present study attempts to fill a critical knowledge gap of BoNT A in tremor management by studying the efficacy of IncobotulinumtoxinA (Xeomin®) injection for hand tremor in essential tremor and idiopathic Parkinson disease…
- Trial name
- NCT02427646
- Testing
- BoNT-A
- Volunteers
- 54 people
- Sponsor
- Western University, Canada
Stroke, Hemiplegia, Spastic
Condensed and Distributed Robotic Therapy in Spastic Stroke Post Botulinum Toxin Injection
The purpose of this project is to examine and compare the immediate and long-term effects of combined Botulinum toxin type A (BoNT-A) injection between condensed and distributed robot-assisted training (RT) programs in patients…
- Trial name
- NCT03321097
- Testing
- condensed RT group, distributed RT group
- Where
- Taiwan
- Volunteers
- 36 people
- Sponsor
- Chang Gung Memorial Hospital
Urinary Incontinence, Urinary Bladder
OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17)
This was a multicenter, randomized, double-blind, parallel-group, multiple-dose study to evaluate the efficacy and safety of BOTOX in adolescents with urinary incontinence due to overactive bladder (OAB) with inadequate…
- Conditions
- Urinary Incontinence, Urinary Bladder, Overactive
- Trial name
- NCT02097121
- Testing
- BOTOX®
- Where
- 39 sites in United States, Australia and 11 more
- Volunteers
- 56 people
- Sponsor
- Allergan
Cervical Dystonia
Dystonia Treatment With Injections Supplemented By Transcranial Magnetic Stimulation
We applied 16 sessions of rTMS over 4 consecutive days for adult patients suffering from cervical dystonia who received botulinum toxin (BoNT) injections on a regular basis.
- Trial name
- D-TWIST (NCT04916444)
- Testing
- rTMS
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Florida
Anxiety, Pain
Relaxing Environment to Lower Anxiety During Onabotulinum Toxin Chemodenervation of the Bladder
Chemodenervation of the bladder with onabotulinum toxin A is an effective treatment option for patients with refractory urgency urinary incontinence (UUI).
- Conditions
- Anxiety, Pain, Burnout, Professional
- Trial name
- RELAX (NCT06319898)
- Testing
- Lavender aromatherapy sticker
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- Wake Forest University Health Sciences
Migraine
Real World Effectiveness of Eptinezumab in Participants With Migraine
The purpose of this study is to examine how eptinezumab compares to other advanced preventive medications in a real-world community setting in adult participants with episodic migraine (EM) or chronic migraine (CM).
- Trial name
- EVEC (NCT05284019)
- Testing
- Eptinezumab, Erenumab, Onabotulinumtoxin-A
- Where
- 10 sites in United States
- Volunteers
- 32 people
- Sponsor
- H. Lundbeck A/S
Urinary Bladder, Overactive
Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder
GSK1358820 is a botulinum neurotoxin A complex that has been approved for the treatment of overactive bladder (OAB) in several countries, however, it has not been approved for OAB treatment in Japan.
- Trial name
- NCT02820844
- Testing
- GSK1358820, Antibiotic therapy, Bladder diary
- Where
- 48 sites in Japan
- Volunteers
- 250 people
- Sponsor
- GlaxoSmithKline
Cerebral Palsy, Muscle Spasticity
Effect of Botox and Vibration on Bone in Children With Cerebral Palsy
Cerebral palsy (CP) is a neuromuscular disorder that affects approximately 800,000 individuals in the U.S. An estimated 70-80% of these individuals have spasticity which affects ambulation and requires management.
- Trial name
- NCT01803464
- Testing
- Low-magnitude vibration, Botox
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- University of Delaware
Benign Prostatic Hyperplasia
Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
This study will evaluate the safety and efficacy of intraprostatic administration of botulinum toxin Type A (BOTOX®) compared with placebo to treat urinary tract symptoms due to benign prostatic hyperplasia.
- Trial name
- NCT01107392
- Testing
- botulinum toxin Type A, Normal saline
- Where
- 8 sites in United States, Canada and 6 more
- Volunteers
- 315 people
- Sponsor
- Allergan
Migraine Disorders
A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine
This open-label study will assess the long-term efficacy, safety, and tolerability of onabotulinumtoxinA administered for prophylaxis of headaches in patients with chronic migraine.
- Trial name
- NCT01516892
- Testing
- onabotulinumtoxinA
- Where
- 32 sites in United States, Australia and 1 more
- Volunteers
- 716 people
- Sponsor
- Allergan
Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children
Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children
The purpose of this study is to assess the efficacy and safety of multiple doses of Dysport used in the treatment of upper limb spasticity (altered skeletal muscle performance) in children with cerebral palsy (CP).
- Trial name
- PUL (NCT02106351)
- Testing
- Botulinum toxin type A
- Where
- 31 sites in United States, Belgium and 6 more
- Volunteers
- 212 people
- Sponsor
- Ipsen
Adductor Spasmodic Dysphonia, Voice Disorders
DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia
Spasmodic Dysphonia (SD) is a neurologic condition causing inappropriate contraction of the laryngeal musculature, leading to abnormal voicing.
- Conditions
- Adductor Spasmodic Dysphonia, Voice Disorders, Spasmodic Dysphonia
- Trial name
- NCT05158166
- Testing
- DaxibotulinumtoxinA
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of California, San Francisco
Spasticity, Post-Stroke
A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects With Post-stroke Upper Limb Spasticity
Botulinum toxin A (GSK1358820) is a sterile, purified type A botulinum neurotoxin complex. In Japan, 240 units of botulinum toxin A are approved as a maximum dose per administration for upper limb spasticity.
- Trial name
- NCT03261167
- Testing
- Botulinum toxin A (GSK1358820)
- Where
- 38 sites in Japan
- Volunteers
- 124 people
- Sponsor
- GlaxoSmithKline